AnaptysBio, Inc. Common Stock (ANAB) is a publicly traded Healthcare sector company. As of May 21, 2026, ANAB trades at $60.06 with a market cap of $1.71B and a P/E ratio of -64.24. ANAB moved +0.50% today. Year to date, ANAB is +39.07%; over the trailing twelve months it is +184.74%. Its 52-week range spans $12.21 to $73.30. Analyst consensus is strong buy with an average price target of $81.27. Rallies surfaces ANAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AnaptysBio Spin-Off Spurs 14.8% Rally as Jemperli Royalty Model Debuts: AnaptysBio completed a spin-off of First Tracks Biotherapeutics and pivoted to royalty management of Jemperli with GSK and imsidolimab with Vanda. A favorable court ruling preserving Jemperli royalty rates triggered a 14.8% stock jump ahead of predicted Q2 EPS loss of $0.72 on roughly $20 million revenue.
| Metric | Value |
|---|---|
| Price | $60.06 |
| Market Cap | $1.71B |
| P/E Ratio | -64.24 |
| EPS | $-0.94 |
| Dividend Yield | 0.00% |
| 52-Week High | $73.30 |
| 52-Week Low | $12.21 |
| Volume | 12 |
| Avg Volume | 0 |
| Revenue (TTM) | $232.39M |
| Net Income | $-26.79M |
| Gross Margin | 0.00% |
11 analysts cover ANAB: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $81.27.